ES2533242T3 - Prevención y tratamiento de afecciones oculares asociadas con el complemento - Google Patents

Prevención y tratamiento de afecciones oculares asociadas con el complemento Download PDF

Info

Publication number
ES2533242T3
ES2533242T3 ES08756130.4T ES08756130T ES2533242T3 ES 2533242 T3 ES2533242 T3 ES 2533242T3 ES 08756130 T ES08756130 T ES 08756130T ES 2533242 T3 ES2533242 T3 ES 2533242T3
Authority
ES
Spain
Prior art keywords
antibody
complement
prevention
binding fragment
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08756130.4T
Other languages
English (en)
Spanish (es)
Inventor
Philip Hass
Yin Jianping
Kenneth Katschke Jr.
Micah Steffek
Christian Wiesmann
Menno Van Lookeren Campagne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2533242(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2533242T3 publication Critical patent/ES2533242T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
ES08756130.4T 2007-05-23 2008-05-22 Prevención y tratamiento de afecciones oculares asociadas con el complemento Active ES2533242T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
US939791P 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Publications (1)

Publication Number Publication Date
ES2533242T3 true ES2533242T3 (es) 2015-04-08

Family

ID=39638868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08756130.4T Active ES2533242T3 (es) 2007-05-23 2008-05-22 Prevención y tratamiento de afecciones oculares asociadas con el complemento

Country Status (28)

Country Link
US (6) US8007791B2 (enExample)
EP (1) EP2152755B1 (enExample)
JP (4) JP5416695B2 (enExample)
KR (1) KR101540126B1 (enExample)
CN (3) CN107096029B (enExample)
AR (1) AR066660A1 (enExample)
AU (1) AU2008256835B2 (enExample)
BR (1) BRPI0811142A8 (enExample)
CA (1) CA2683498A1 (enExample)
CL (1) CL2008001498A1 (enExample)
CY (1) CY1116062T1 (enExample)
DK (1) DK2152755T3 (enExample)
ES (1) ES2533242T3 (enExample)
HK (1) HK1207327A1 (enExample)
HR (1) HRP20150281T1 (enExample)
IL (2) IL201476A (enExample)
MX (1) MX2009012422A (enExample)
PE (1) PE20090294A1 (enExample)
PH (1) PH12013500992B1 (enExample)
PL (1) PL2152755T3 (enExample)
PT (1) PT2152755E (enExample)
RS (1) RS53901B1 (enExample)
RU (2) RU2522976C2 (enExample)
SG (1) SG10201401404RA (enExample)
SI (1) SI2152755T1 (enExample)
TW (2) TW201417829A (enExample)
WO (1) WO2008147883A1 (enExample)
ZA (1) ZA200907028B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001084149A2 (en) * 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
HUE026423T2 (en) * 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
SI2097455T1 (sl) * 2006-11-02 2015-03-31 Genentech, Inc. Humanizirana protitelesa proti faktorju tipa d
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
BRPI0918496A2 (pt) * 2008-09-02 2019-09-24 Novartis Ag composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
CA2807554C (en) * 2010-08-05 2021-10-26 Forsight Vision4 Inc. Implantable therapeutic device
SG190078A1 (en) * 2010-11-01 2013-06-28 Genentech Inc Predicting progression to advanced age-related macular degeneration using a polygenic score
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
JP6154897B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
ES2647124T3 (es) 2012-06-28 2017-12-19 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
EP2867226B1 (en) 2012-06-28 2018-11-14 Novartis AG Complement pathway modulators and uses thereof
JP6238980B2 (ja) 2012-07-12 2017-11-29 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
WO2014160884A1 (en) 2013-03-28 2014-10-02 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
CA2926812A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
CN105764533A (zh) * 2013-10-25 2016-07-13 儿童医疗中心有限公司 治疗或预防视网膜血管疾病的方法
CR20160561A (es) 2014-05-01 2017-05-03 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
US10435441B2 (en) * 2015-09-23 2019-10-08 Sangamo Therapeutics, Inc. HTT repressors and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
NZ741780A (en) 2015-10-30 2019-11-29 Genentech Inc Anti-htra1 antibodies and methods of use thereof
JP6911026B2 (ja) 2015-10-30 2021-07-28 ジェネンテック， インコーポレイテッド Ｄ因子活性及びｄ因子阻害剤の力価を測定する方法
US10640540B2 (en) 2015-12-23 2020-05-05 Greenovation Biotech Gmbh Polypeptides for inhibiting complement activation
CA3011819A1 (en) * 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
US11434279B2 (en) * 2017-02-10 2022-09-06 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
EP3999078A4 (en) * 2019-07-18 2023-06-14 Pandorum Technologies Private Limited METHODS FOR CULTURING MESENCHYMATOUS STEM CELLS, PRODUCTS RELATED AND THEIR APPLICATIONS

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2000036102A2 (en) 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO1999040100A1 (en) 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 human secreted proteins
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) * 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
ATE410512T1 (de) 1997-11-21 2008-10-15 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
CN101298481A (zh) * 1998-02-20 2008-11-05 吉宁特有限公司 补体活化的抑制剂
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
EP1490386B1 (en) 1998-03-10 2008-08-13 Genentech, Inc. Novel polypeptide and nucleic acids encoding the same
CA2340794A1 (en) 1998-08-27 2000-03-09 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
DK1140175T3 (da) * 1998-12-21 2006-08-14 Ludwig Inst Cancer Res Antistoffer mod trunkeret VEGF-D og anvendelser deraf
ES2327785T3 (es) 1998-12-22 2009-11-03 Genentech, Inc. Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EE05497B1 (et) 1999-03-11 2011-12-15 Rmf Dictagene S.A. Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
UA72943C2 (uk) 1999-11-02 2005-05-16 Ульяновскій Государствєнний Тєхніческій Унівєрсітєт Спосіб очищення рідини від феромагнітних частинок (варіанти) і пристрій для його здійснення (варіанти)
EP1234030A4 (en) 1999-11-19 2003-05-07 Human Genome Sciences Inc 18 HUMAN SECRETED PROTEINS
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1309620A2 (en) 2000-06-23 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003258714A1 (en) 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
HUE026423T2 (en) 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
SI2097455T1 (sl) * 2006-11-02 2015-03-31 Genentech, Inc. Humanizirana protitelesa proti faktorju tipa d
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
JP2014087346A (ja) 2014-05-15
RU2522976C2 (ru) 2014-07-20
CN101754980A (zh) 2010-06-23
JP5416695B2 (ja) 2014-02-12
IL248552A0 (en) 2016-12-29
DK2152755T3 (en) 2015-03-02
RS53901B1 (sr) 2015-08-31
HK1207327A1 (en) 2016-01-29
US20130302333A1 (en) 2013-11-14
PH12013500992B1 (en) 2018-12-14
AU2008256835A1 (en) 2008-12-04
IL201476A0 (en) 2010-05-31
EP2152755B1 (en) 2014-12-31
KR20100033973A (ko) 2010-03-31
HRP20150281T1 (hr) 2015-04-10
MX2009012422A (es) 2009-12-04
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
PL2152755T3 (pl) 2015-06-30
AR066660A1 (es) 2009-09-02
US20180079826A1 (en) 2018-03-22
PT2152755E (pt) 2015-04-01
US20160272726A1 (en) 2016-09-22
PE20090294A1 (es) 2009-03-27
IL201476A (en) 2016-11-30
JP2016145205A (ja) 2016-08-12
KR101540126B1 (ko) 2015-07-28
CN107096029B (zh) 2021-02-26
US8268310B2 (en) 2012-09-18
JP2010528047A (ja) 2010-08-19
RU2014113046A (ru) 2015-10-10
PH12013500992A1 (en) 2016-01-25
SG10201401404RA (en) 2014-08-28
CA2683498A1 (en) 2008-12-04
TW201417829A (zh) 2014-05-16
US8007791B2 (en) 2011-08-30
US20110282034A1 (en) 2011-11-17
CN101754980B (zh) 2014-10-29
RU2009147744A (ru) 2011-06-27
WO2008147883A1 (en) 2008-12-04
HK1139161A1 (en) 2010-09-10
CN104367999A (zh) 2015-02-25
SI2152755T1 (sl) 2015-05-29
CY1116062T1 (el) 2017-02-08
ZA200907028B (en) 2010-12-29
CN107096029A (zh) 2017-08-29
CL2008001498A1 (es) 2009-06-12
US20130052685A1 (en) 2013-02-28
BRPI0811142A8 (pt) 2018-12-18
TW200904471A (en) 2009-02-01
WO2008147883A8 (en) 2013-05-23
JP2017197577A (ja) 2017-11-02
EP2152755A1 (en) 2010-02-17
US20090181017A1 (en) 2009-07-16
TWI419704B (zh) 2013-12-21
US8497094B2 (en) 2013-07-30

Similar Documents

Publication Publication Date Title
ES2533242T3 (es) Prevención y tratamiento de afecciones oculares asociadas con el complemento
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
AR123876A2 (es) Composición farmacéutica de anticuerpos anti-cgrp
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
PE20110797A1 (es) Anticuerpos anti mn
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
CL2012000518A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de mieloma en un mamífero (div. sol. 3615-07).
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
PE20120816A1 (es) Composiciones que comprenden anticuerpos de dickkopf-1
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
AR099812A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
ES2722824T3 (es) Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
AR077595A1 (es) Tratamientos de combinacion
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.
EA201070888A1 (ru) Антитела и их производные
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
PE20161390A1 (es) Anticuerpos multiespecificos
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40